Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORDETTE-28 vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Prevention of pregnancy
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
One tablet orally once daily for 28 consecutive days.
DHIVY is not a recognized drug. No dosing information available.
Ethinyl estradiol: 13-27 hours (mean 17 hours); Levonorgestrel: 11-45 hours (mean 24 hours); clinical context: steady-state reached after 5-7 days.
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Ethinylestradiol is metabolized primarily via CYP3A4; levonorgestrel is metabolized via CYP3A4 and to a lesser extent CYP2C19 and CYP2C9.
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal: ~50% as metabolites, ~20% unchanged; Fecal: ~30% as metabolites; Biliary: minimal.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Ethinyl estradiol: ~97% bound to albumin; Levonorgestrel: ~98% bound to SHBG (sex hormone-binding globulin) and albumin.
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Ethinyl estradiol: 2.9-4.3 L/kg; Levonorgestrel: 1.8-2.1 L/kg; clinical meaning: extensive tissue distribution, not limited to plasma.
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: Ethinyl estradiol ~45% (first-pass metabolism); Levonorgestrel ~100% (minimal first-pass).
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for fluid retention and hyperkalemia.
Not applicable.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment recommended.
Not applicable.
Not indicated for use in pediatric patients before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally daily for 28 days.
Not applicable.
Not indicated for use in postmenopausal women. No specific dose adjustment in elderly patients without contraindications, but consider increased risk of thromboembolism and cardiovascular events.
Not applicable.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
No FDA black box warnings.
Risk of thrombotic and thromboembolic events (venous and arterial),Risk of myocardial infarction and stroke,Increased risk of hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Exacerbation of hereditary angioedema,Chloasma,Retinal thrombosis,Depression,Reduced efficacy with enzyme-inducing drugs,Irregular bleeding,Amenorrhea and oligomenorrhea,Lactation
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Known or suspected pregnancy,Current or past history of thrombotic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected breast cancer or estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Hepatic adenoma or carcinoma, known or suspected,Active liver disease with impaired liver function,Hypersensitivity to any component,Cigarette smoking in women over 35 years old
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
Avoid large amounts of grapefruit or grapefruit juice as they can increase ethinyl estradiol levels. St. John's wort may reduce contraceptive efficacy. No other specific dietary restrictions. A well-balanced diet is recommended.
No data available for DHIVY.
FDA Pregnancy Category X. Estrogens and progestins are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defects. Use during first trimester is associated with congenital anomalies; second and third trimester use may cause genitourinary abnormalities and delayed fetal development.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Excreted in human breast milk in small amounts. M/P ratio not established. May reduce milk production and quality. Use during breastfeeding is not recommended; consider alternative contraception or discontinue nursing.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Contraindicated in pregnancy. No dose adjustments are applicable; drug should be discontinued immediately upon confirmed or suspected pregnancy.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
Nordette-28 is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. In case of missed pills, follow package instructions; if two or more pills are missed, use backup contraception for 7 days. The risk of venous thromboembolism is increased in smokers over age 35; strongly advise smoking cessation. Start the first pill on the first day of menses or first Sunday after onset. Monitor for breakthrough bleeding, especially in the first few cycles. Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take one pill daily at the same time each day to maintain hormone levels.,If you miss a pill, take it as soon as remembered; if more than 24 hours late, follow package directions and use backup contraception.,Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots.,Use additional non-hormonal contraception if you vomit or have severe diarrhea within 3-4 hours of taking a pill.,Nordette-28 does not protect against sexually transmitted infections; use condoms for STI prevention.
Do not use this drug without correct identification.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORDETTE-28 vs DHIVY, answered by our medical review team.
NORDETTE-28 is a Combined Oral Contraceptive that works by Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORDETTE-28 and DHIVY depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORDETTE-28 is: One tablet orally once daily for 28 consecutive days.. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORDETTE-28 and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORDETTE-28 is classified as Category C. FDA Pregnancy Category X. Estrogens and progestins are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defects. Use duri. DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.